Cerevel Therapeutics drug tavapadon met the main and secondary goals of a pivotal Parkinson’s disease clinical trial. That drug and others will join the neuroscience portfolio of AbbVie, which is in the process of acquiring Cerevel.
The post Novel Parkinson’s Disease Drug Will Join AbbVie With Positive Phase 3 Data In Hand appeared first on MedCity News.